A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer

NCT07121244 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Locoregionally Recurrent Hormone-receptor Positive Breast Cancer
Metastatic Hormone Receptor Positive Breast Cancer

Interventions

DRUG: 68Ga-R11228
DRUG: 177Lu-R11228

Sponsor

Radionetics Oncology